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A B S T R A C T
Objectives
This is a protocol for a Cochrane Review (intervention). The objectives are as follows:
The primary objective of the review is to assess the eBicacy of psychological interventions for improving adherence to inhaled therapies
in people with cystic fibrosis (CF). A secondary objective is to establish the most eBective components, or behaviour change techniques
(BCTs), of interventions for improving adherence to inhaled therapies in people with CF, using the BCT Taxonomy version 1 (Michie 2013).
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B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is a chronic, genetic condition aBecting over
10,500 people in the UK (UK CF Registry 2019), 30,000 people in
the USA (CF Foundation Patient Registry 2019), and around 90,000
people worldwide (Bell 2020). One in 25 people in the UK carry
the faulty gene that causes CF, usually without realising it (Cystic
Fibrosis Trust 2018). People with CF are prone to recurrent chest
infections, or pulmonary exacerbations, due to the build-up of
thick, sticky mucus, or sputum, in their lungs and digestive systems.
Although people with CF are living longer, their life expectancy
remains well below average, and the median predicted survival age
of someone born with CF in 2018 ranges between 47.3 years in the
UK (UK CF Registry 2018), 47.4 years in the USA (CF Foundation
Patient Registry 2019), and 52.1 years in Canada (Cystic Fibrosis
Canada 2019). As lung disease is the primary cause of morbidity
and mortality in people with CF, nebulised medications, or inhaled
therapies, are usually prescribed (ECFS Patient Registry 2017),
with multiple trials demonstrating their eBicacy (Smith 2018; Yang
2018). These treatments are delivered directly to the lungs, thereby
reducing side eBects, and may include antibiotics to treat or control
infections (e.g. tobramycin), mucolytics to thin sputum making it
easier to clear (e.g. dornase alfa), and osmotics to draw water into
the sputum making it easier to cough up (e.g. hypertonic saline).
Whilst advances in medicine mean that many of the symptoms
of CF can be managed eBectively, eBective management
itself requires people living with CF to complete a complex
daily treatment regimen, comprising daily chest physiotherapy,
pancreatic enzymes, nutritional supplements, and inhaled or
nebulised therapies. A minimum of one to three nebulised
treatments per day are usually prescribed, depending on an
individual's characteristics (Hoo 2016), with treatments taking an
average of 41 minutes per day (Sawicki 2009).
Treatments are only eBective if they are taken, yet evidence
suggests that in high-income countries, only 50% of people
with a chronic condition adhere to treatment recommendations
(WHO 2003). As with other chronic conditions, low adherence to
treatments for CF, including inhaled therapies, is a global problem,
with widespread implications for the individual and their family, for
CF teams supporting the individual, and for society as a whole. Low
adherence to all treatments is associated with an increased number
of pulmonary exacerbations requiring intravenous (IV) antibiotics
(Eakin 2011) and hospitalisations, which incur higher healthcare
costs (Quittner 2014). Two trials have demonstrated the importance
of adherence to inhaled therapies on health outcomes, with higher
adherence to dornase alfa being associated with a shorter length
of hospital stay (Nasr 2013); and individuals collecting four or more
courses of nebulised tobramycin per year being 60% less likely to
be admitted to hospital than those collecting two or fewer courses
(Briesacher 2011).
Adherence refers to "the extent to which the patient’s behaviour
matches agreed recommendations from the prescriber" (Horne
2005). This term is more patient-centred and is therefore
preferable to the outdated term of compliance, which is
"the extent to which the individual’s behaviour matches the
prescriber's recommendations" (Haynes 1979). There are diBerent
methods of measuring adherence, each of which has varying
degrees of objectivity and validity. Self-reported measures (e.g.
questionnaires and diaries) are inexpensive and easy to administer,
but are subject to a range of biases, including social desirability
bias and recall bias (Osterberg 2005). Objective count measures
(e.g. medication possession ratio (MPR)) address these biases, but
they too are prone to overestimation as they do not guarantee
the treatment has been taken (Osterberg 2005). Objective recorded
measures (e.g. electronic monitoring devices) are a more accurate,
albeit expensive, method of measuring adherence (Osterberg
2005). With the development of chipped nebulisers (e.g. Philips
I-neb® and PARI eTrack®) which record time- and date-stamped
data, it is possible to measure adherence to inhaled therapies using
this method. Trials using objective recorded measures suggest that
adherence to inhaled therapies in people with CF is around 31%
to 36% in adults (Daniels 2011; Hoo 2019; Hoo 2020) and 65% to
67% in children or adolescents (Ball 2013; McNamara 2009). The
discrepancy between objective and subjective measurement has
also been highlighted (Daniels 2011).
Description of the intervention
Interventions that specifically aim to improve adherence
to prescribed medications vary widely (Nieuwlaat 2014).
Psychological interventions aimed at improving adherence to
inhaled therapies in people with CF can therefore take many forms
and may be targeted at: people with CF (e.g. patient education,
medication reminders, rewards, psychological therapies); their
families (e.g. increasing supervision with medication, family
therapy); or the multidisciplinary team (MDT) providing specialist
care to the person with CF (e.g. training clinicians to communicate
more eBectively with patients). Interventions may be delivered
face-to-face, over the phone, or using digital technology
(e.g. smartphone applications or 'apps' that include rewards,
reminders, or providing feedback on treatment-taking behaviour).
Given the complexity of many adherence interventions tested to
date (Nieuwlaat 2014), and the way in which complex interventions
are reported or described in the literature, it is oPen diBicult
to determine the content, or the 'active ingredients', of eBective
interventions that bring about change (Michie 2009). These 'active
ingredients', or behaviour change techniques (BCTs), are defined
as the "observable, replicable and irreducible components of an
intervention designed to alter or redirect causal processes that
regulate behaviour" (Michie 2013). OPen, few details are provided
about the BCTs used in interventions, and the terminology
used to describe interventions is inconsistent. This makes it
diBicult to replicate eBective interventions, because the core
components, or ‘active ingredients’, are not known, and time and
resources are wasted because ineBective techniques continue to be
implemented (Michie 2009). This review therefore aims to identify
the content, or the ‘active ingredients’, of interventions, in terms of
the BCTs used, in order to establish the most eBective components
of interventions for improving adherence to inhaled therapies
in people with CF. This will aid understanding of the causal
mechanisms underlying adherence behaviour, which will help
inform the design of more eBective, consistent and cost-eBective
interventions in the future (Michie 2009). A reliable, consensually-
agreed taxonomy (BCT Taxonomy version 1; BCTTv1) contains 93
BCTs and provides a common language to identify and describe
intervention content (Michie 2013). At least two other reviews have
used the BCTTv1 to code the BCTs present in complex interventions
(Black 2020; Lawrenson 2016). Psychological interventions for
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improving adherence to inhaled therapies in people with CF may
incorporate one or more BCTs (e.g. 'problem-solving', defined as
"analysing, or prompting the person to analyse, factors influencing
the behaviour and generating or selecting strategies that include
overcoming barriers and/or increasing facilitators" (Michie 2013)).
In this review, interventions will be compared to either an active
control group or standard care, which usually consists of an annual
review or routine reviews (or a combination of both) with a
specialist CF MDT.
How the intervention might work
Reasons for non-adherence are wide-ranging and varied, and
understanding these reasons is crucial in order to assist with the
development of eBective, evidence-based interventions. Previous
trials have attempted to understand the factors influencing
adherence to treatments in people with CF, and commonly
reported reasons include being too busy, forgetting to take a
treatment, not having the time to take treatments, and the level
of treatment burden (Bregnballe 2011; Dziuban 2010; George 2010;
Modi 2006; Sawicki 2015). Treatment beliefs (e.g. lack of perceived
benefit, feeling embarrassed about taking treatments in public,
believing it is acceptable to miss treatments) have also been
reported to influence adherence to treatments in people with CF
(Bregnballe 2011; Bucks 2009; Dziuban 2010; George 2010; Sawicki
2015). This is consistent with the Necessity-Concerns Framework
(Horne 1999), which posits that beliefs about the necessity of
treatments, and concerns about potential adverse consequences,
can influence adherence and non-adherence to treatments across
a wide range of conditions and medications (Horne 2013).
Whilst treatment beliefs and concerns (i.e. conscious or reflective
motivation) may be an important influence on treatment-taking,
it is also important to consider the role of automatic motivation
influences, with recent trials highlighting the role of habit (i.e.
"automatically experiencing an urge to use a nebuliser" (Hoo
2019a)) on adherence to inhaled therapies in adults with CF (Arden
2019; Hoo 2017; Hoo 2019a). Objective adherence data, collected
using date- and time- logging nebulisers, have demonstrated that,
amongst adolescents with CF, adherence to inhaled therapies is
greatest on school days compared to weekends or holidays (Ball
2013), despite this being a time when adolescents are likely to be
busiest and are therefore more susceptible to miss treatments due
to burden (Hoo 2017).
Given the complexity and multifactorial nature of adherence,
interventions aimed at improving adherence to inhaled therapies
are likely to be complex, or contain several interacting components
(Craig 2008). A ‘one size fits all’ intervention is therefore unlikely
to be eBective, as it will need to address issues of capability,
opportunity, and motivation (Arden 2019), as highlighted in
the COM-B (capability, opportunity, motivation and behaviour)
model of behaviour (Michie 2011). Interventions may include
reminders or alarms to target forgetting, although evidence for the
eBicacy of reminders on adherence is limited (Choudhry 2017).
Although forgetting is oPen understood to be ‘unintentional’ non-
adherence, it may be given as a reason to justify ‘intentional’
non-adherence (Arden 2019; Drabble 2019; George 2010), in a
more socially acceptable way (Drabble 2019). Interventions may
target the individual's or family members' (e.g. parent) beliefs
about the necessity of treatments, and concerns about potential
adverse consequences, through psycho-education or problem-
solving. They may also focus on supporting people with CF
to develop routines and build habits for treatment-taking, e.g.
through the use of action planning. Feedback on treatment-taking
behaviour may be provided (Demonceau 2013), and interventions
may include people with CF self-monitoring their adherence to
inhaled therapies, e.g. through the use of chipped nebulisers and
digital technology applications. Healthcare professionals also have
an important role in supporting adherence to inhaled therapies in
adults with CF (Arden 2019). National Institute for Health and Care
Excellence guidelines recommend the use of a non-judgemental
approach which involves asking open questions and not making
assumptions, to promote open and honest conversations in
relation to adherence (NICE 2009). Interventions may therefore
involve training CF MDT members to communicate more eBectively
with individuals in relation to adherence, or teaching healthcare
professionals how to address necessity beliefs and concerns during
consultations (Chapman 2015).
Why it is important to do this review
A previous Cochrane Review concluded that establishing "eBective
ways to help people follow medical treatments could have far
larger eBects on health than any treatment itself" (Haynes 2002).
Furthermore, “simplifying the treatment burden” and "improving
and sustaining adherence to treatment" have been identified as
top 10 CF research priorities in the James Lind Alliance Priority
Setting Partnership (Davies 2020; Rowbotham 2017). Adherence
research has also been identified as a high priority by the World
Health Organisation (WHO 2008). Despite this, there have been
no published systematic reviews to assess the eBectiveness of
psychological interventions for improving adherence to inhaled
therapies in people with CF. A previous Cochrane Protocol which
focused on adherence to all treatments in CF was withdrawn (Jones
2015). The current Cochrane Review will provide a more detailed
focus on CF than general adherence reviews (Nieuwlaat 2014) and
will expand upon other CF reviews focused on self-management
interventions (Savage 2014) and psychological interventions for
improving a range of outcomes (Goldbeck 2014). Interventions
will be coded in order to establish which BCTs are most eBective
at improving adherence to inhaled therapies in people with CF.
By identifying the 'active ingredients' of interventions, the results
of this review will help researchers, intervention designers and
clinicians better support people with CF. By focusing on inhaled
therapies, this review will complement other reviews planned or
produced by the group on the theme of adherence (Jones 2020;
Smith 2020).
O B J E C T I V E S
The primary objective of the review is to assess the eBicacy of
psychological interventions for improving adherence to inhaled
therapies in people with cystic fibrosis (CF). A secondary objective
is to establish the most eBective components, or behaviour change
techniques (BCTs), of interventions for improving adherence to
inhaled therapies in people with CF, using the BCT Taxonomy
version 1 (Michie 2013).
Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis (Protocol)
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs); we will
consider quasi-RCTs if we can reasonably assume that the baseline
characteristics are similar in both groups. We will include RCTs of
parallel design and cluster RCTs; we will only include first-period
data from cross-over RCTs due to the likely carry-over eBects of the
intervention. We will include published and unpublished trials, as
well as those published as abstracts only.
Types of participants
We will include participants of any age, gender, and ethnicity who
have a diagnosis of CF and who are prescribed inhaled therapies
(as confirmed in the methodology of each included RCT). We
will include participants based in either a hospital or community
setting. Trials that include participants with CF and participants
with other chronic conditions will only be included if there is a
distinction made between the diBerent participant groups (so that
non-CF participants with other chronic conditions can be excluded
from our analyses). We will also include MDTs or families of people
with CF if they are the target participants of an intervention aimed
at improving adherence to inhaled therapies in people with CF.
A previous Cochrane Review has highlighted the inclusion bias
likely to be present in adherence trials, with many interventions
conducted using convenience samples in which participants have
higher than average adherence at baseline (Nieuwlaat 2014). This is
an important methodological issue to consider as this may reduce
the power of an included trial to achieve the primary outcome.
Types of interventions
We will aim to assess all potential psychological interventions for
improving adherence to inhaled therapies in people with CF as
detailed above (Description of the intervention) and which are
specifically aimed at people with CF, the families of people with CF,
or specialist CF MDTs. We will include trials that report at least one
measure of adherence as an outcome.
We will use the BCTTv1 (Michie 2013) to identify the BCTs
present in interventions in the included trials in order to establish
which BCTs are most eBective at improving adherence to inhaled
therapies in people with CF. We will also code the BCTs present
in the active control groups, as the content and eBectiveness of
these interventions may vary considerably (de Bruin 2016). Given
the wide variety of intervention targets included (i.e. children,
adolescents and adults with CF, families of people with CF, and
specialist CF MDTs), it may not be appropriate to combine the
results from diBerent populations in statistical analysis.
Types of outcome measures
Primary outcomes
1. Adherence to inhaled therapies (measured using both objective
and subjective measures)
a. objective recorded measures (e.g. electronic monitoring
devices such as Philips I-neb® and PARI eTrack® nebulisers
which record date- and time-stamped data)
b. objective count measures (e.g. MPR)
c. subjective measures (e.g. self-reported adherence;
questionnaires; participant diaries)
2. Treatment-related adverse events
a. anxiety as measured by a validated anxiety scale, e.g. GAD-7
(Spitzer 2006)
b. depression as measured by a validated depression scale, e.g.
PHQ-8 (Kroenke 2009)
We will include trials with a measure of adherence regardless of if it
is a primary or secondary outcome in the trials. If an included trial
measures adherence using more than one type of measure, then
the most reliable measure will be reported (i.e. objective measures
will be preferentially reported over subjective measures, using the
hierarchy of validity above). This is consistent with other Cochrane
Reviews looking at adherence (Cross 2020; Hollands 2019).
Adherence is expected to be typically defined as a continuous
measure (e.g. total number of doses taken as a percentage of
the target number of doses prescribed over a given time period).
Alternatively, it may be defined as a dichotomous outcome, e.g.
reporting whether the treatment is being used to a pre-specified
degree (e.g. adherence for X number of days) or ‘adherent' versus
'non-adherent', although this latter approach is overly simplistic
and unlikely in our opinion.
Where possible, adherence will refer to 'normative adherence', a
measure that takes into account a person's characteristics when
defining the minimum required treatment regimen (Hoo 2016). This
is in contrast to 'unadjusted adherence', which is where a treatment
regimen may be informed by considerations other than treatment
eBectiveness (e.g. a regimen based on what people with CF feel they
can realistically manage rather than a regimen that has been driven
by clinical evidence) (Hoo 2016).
Secondary outcomes
1. Quality of life (QoL) as measured by a validated QoL
questionnaire, e.g. CFQ-R (Quittner 2009)
2. Lung function (absolute change or percentage change
compared to baseline values or both), measured in forced
expiratory volume at one second (FEV1) L or per cent (%)
predicted
3. Pulmonary exacerbations (using the measure specified in the
methodology of each trial, e.g. modified Fuchs criteria (Bilton
2011))
a. number of exacerbations
b. time to next exacerbation
c. duration of exacerbations (as measured by the total number
of IV days)
If outcomes are reported at multiple time points, we will extract
data from all time points. We will group outcome data into those
Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis (Protocol)
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measured at up to three months; over three months and up to six
months; over six months and up to 12 months; and over 12 months.
If trials record outcome data at other time periods, then we will
consider examining these as well.
Search methods for identification of studies
We will search for all relevant published and unpublished trials
without restrictions on language, year or publication status. If we
identify non-English trials, we will assess these and if necessary,
translate these with the assistance of a native speaker (e.g. by
posting a request on Cochrane TaskExchange).
Electronic searches
The Cochrane Cystic Fibrosis and Genetic Disorders Group's
Information Specialist will conduct a systematic search of the
Group's Cystic Fibrosis Trials Register for relevant trials using the
following terms: treatment adherence OR mental health in CF OR
behaviour.
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated with each new issue of the Cochrane Library),
weekly searches of MEDLINE, a search of Embase to 1995 and the
prospective handsearching of two journals - Pediatric Pulmonology
and the Journal of Cystic Fibrosis. Unpublished work is identified
by searching the abstract books of three major CF conferences:
the International Cystic Fibrosis Conference; the European Cystic
Fibrosis Conference and the North American Cystic Fibrosis
Conference. For full details of all searching activities for the register,
please see the relevant section of the Cochrane Cystic Fibrosis and
Genetic Disorders Group's website.
The review authors will search the following databases:
• PubMed (www.ncbi.nlm.nih.gov/pubmed/ 1946 to present);
• PsycINFO Ovid (1806 to present);
• Scopus (1823 to present);
• OpenGrey (www.opengrey.eu/).
They will also search the following trials registries:
• World Health Organization International Clinical Trials Registry
Platform (WHO ICTRP) (apps.who.int/trialsearch);
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov).
See the appendices for details of the search strategies (Appendix 1).
Searching other resources
We will check the reference lists of included trials and any relevant
systematic reviews identified for further references to relevant
trials. We will contact leaders and organisations in the field to
obtain additional information on relevant trials.
Data collection and analysis
Selection of studies
Two review authors (SD, LC) will independently screen all titles
and abstracts identified from the search for their relevance for
inclusion in the review based on trial design, types of participants
and interventions (as detailed above). We will obtain full-text
publications of those deemed either eligible or potentially eligible,
as well as for those where eligibility is unclear. We will identify and
exclude duplicates and will collate multiple reports of the same trial
so that each trial, rather than each report, is the unit of interest in
the review. We will independently screen the full-text publications
and identify trials for inclusion in the review according to the
predetermined eligibility criteria in a prespecified order. We will
record the reasons for exclusion of trials in the table 'Characteristics
of excluded studies'. The two authors (SD, LC) will resolve any
disagreements regarding the inclusion of a trial by discussion or
through consultation with a third author if necessary (CG or DCC).
Data extraction and management
We will develop a data extraction form and pilot this, undertaking
any amendments as necessary. We will extract the following main
sets of data from each included trial:
• trial details (lead author; date);
• methods (trial design and timetable, randomisation, allocation
concealment);
• participants (participant condition(s) and demographics, age,
gender, race or ethnicity, socioeconomic status, numbers of
participants in each trial arm, trial participant inclusion criteria);
• interventions (content and format of interventions, including
details of information provided, intervention setting and
delivery provider);
• outcomes (outcome measures, assessment time points,
analysis, results);
• additional comments.
Two review authors (SD, LC) will independently extract data and will
resolve discrepancies through discussion, or through consultation
with a third author if necessary (CG or DCC). Any authors involved in
an included trial will not be involved in data extraction for that trial.
The lead review author (SD) will enter the data into RevMan, with
the second review author (LC) checking the accuracy of the data
entry (RevMan 2020).
We will report outcome data at diBerent time points (up to three
months; over three months and up to six months; over six months
and up to 12 months; and over 12 months). If trial investigators
record outcome data at other time periods, then we will consider
examining these as well.
We will code the extracted intervention descriptions into
component BCTs using the BCTTv1, an established taxonomy of
93 BCTs, as a coding framework (Michie 2013). We will code BCTs
for each intended recipient; we will also code each intervention
separately, including control arms and will code BCTs as 'present' or
'absent' for each intervention description. As originally described
(Michie 2009), and highlighted in a Cochrane Review, complex
behaviour change interventions are oPen poorly reported which
makes it challenging to identify the intervention content or BCTs
used (Lawrenson 2016). As such, we will contact the authors of
included trials about the content of the intervention if there is
insuBicient information available (Michie 2013). We will request
additional materials or information that provides further detail on
the content of the intervention (e.g. trial protocol, letters sent to
participants). We will code received materials using the taxonomy
in the same manner as for the corresponding published reports.
Two review authors (SD, LC) will independently conduct BCT
Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis (Protocol)
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coding, resolving discrepancies by discussion or by consultation
with a third author (CG or DCC) if necessary.
We will narratively record and report any results that we are not
able to formally analyse in RevMan (RevMan 2020).
Assessment of risk of bias in included studies
Two review authors (SD, LC) will independently assess the risk
of bias (or methodological quality) for each included trial, with
any disagreements resolved by discussion or by consultation
with a third author (CG or DCC) if necessary. We will contact
the trial authors for additional information about the trial
methods if necessary. We will use the Cochrane risk of bias
tool to assess the following domains: sequence generation or
randomisation; allocation concealment; blinding of participants,
personnel and outcomes assessors; incomplete outcome data; and
selective outcome reporting (Higgins 2011). However, blinding of
participants and personnel is typically not possible in trials of
psychological interventions. As such, the assessment of blinding
will only include the outcome assessors. We will categorise the
overall risk of bias of included trials as low, high, or unclear
(according to the criteria specified Higgins 2011), and present this
(along with a justification for the judgement) in the tables.
Any authors involved in an included trial will not assess that trial for
risk of bias or GRADE.
Measures of treatment e9ect
If appropriate (e.g. when interventions, participants and the
underlying clinical questions and outcomes are similar enough
for pooling to make sense), we will conduct a meta-analysis.
When single trials report multiple trial arms, we will only include
the relevant arms. For continuous variables, we will calculate
mean diBerences (MDs) with 95% confidence intervals (CIs); or
standardised mean diBerences (SMDs) with 95% CIs when the
same outcome is measured on diBerent scales. For dichotomous
variables, we will present risk ratios (RRs) with 95% CIs. For
data reported as rates or count data (e.g. number of pulmonary
exacerbations), we will calculate rate ratios with 95% CIs. We expect
that most of the data we collect in this review will be continuous
given the outcome measures listed (e.g. adherence to inhaled
therapies; lung function, QoL).
We will narratively describe any skewed data reported as medians
and ranges.
Unit of analysis issues
For cluster RCTs, we will only include data in the meta-analyses if
the available data have been adjusted to account for the clustering
(or can be adjusted, based on recommendations (Higgins 2019)).
For cross-over RCTs, we will include data from the first period only
as we cannot exclude a carry-over eBect of the intervention.
Dealing with missing data
If data are missing from the included trials, we will contact the
original trial authors (by email, letter or telephone) to obtain these
data. If data such as standard deviations (SDs) are missing, where
appropriate, we will calculate these from standard errors (SEs), CIs,
t-values or P values (if reported) (Deeks 2019).
Assessment of heterogeneity
We will assess clinical and methodological heterogeneity by
considering the variation in the characteristics of the participants,
interventions, outcomes and trial designs. We will visually inspect
forest plots and use the Chi2 test and the I2 statistic to measure
heterogeneity among the trials included in each analysis. We will
consider an I2 value greater than 50% to represent substantial
heterogeneity (Higgins 2011).
Assessment of reporting biases
We will use a comprehensive search strategy, which includes
searching for unpublished trials (grey literature) and searching
trials registers (see Search methods for identification of studies) to
minimise reporting biases. We will contact the trial authors for the
full data or the reason for not publishing the data, if data are not
reported or published in full. If we are able to pool more than 10
trials, we will use funnel plots to assess the possibility of publication
bias (Page 2019).
Data synthesis
If trials are suBiciently similar in terms of participants, eligibility
criteria, interventions (type and intent) and outcomes (including
the timeframe of follow-up and type of measure used), we
will consider meta-analysis as described above (Assessment of
heterogeneity). We will use a random-eBects model and will
perform a sensitivity analysis using a fixed-eBect model. If we
are unable to undertake meta-analyses (e.g. if there are too few
included trials or if there is a substantial level of heterogeneity), we
will present a narrative synthesis of the included trials.
Subgroup analysis and investigation of heterogeneity
If suBicient data are available, we will conduct subgroup analyses
with respect to:
1. the target intervention participants (e.g. children and
adolescents with CF; adults with CF; families of people with CF;
or MDTs). In trials that include participants with a range of ages
(i.e. children and adolescents or adults or unspecified), we will
classify adults with CF as 18 years and over and children and
adolescents with CF as under 18 years of age; and
2. the BCTs used.
If appropriate, we will investigate the impact of type and number of
BCTs on eBect size by meta-regression.
Sensitivity analysis
If we can include a suBicient number of trials in any meta-analysis,
we will undertake sensitivity analyses to assess the robustness of
the results by excluding trials with an unclear or high risk of overall
bias. This may include excluding trials in which adherence was
measured using subjective methods (e.g. self-reported adherence;
questionnaires; participant diaries).
Summary of findings table
We will develop a summary of findings table for each comparison
using the following outcomes at the 'over six months and up to 12
months' time point:
Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis (Protocol)
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1. adherence to inhaled therapies (% completed treatments)
(reported using SMD for all results combined from six to 12
months);
2. change from baseline in anxiety (as measured by a validated
anxiety scale, e.g. GAD-7 (Spitzer 2006));
3. change from baseline in depression (as measured by a validated
depression scale, e.g. PHQ-8 (Kroenke 2009));
4. change from baseline in QoL (as measured by a validated QoL
questionnaire, e.g. CFQ-R (Quittner 2009));
5. change from baseline in FEV1 % predicted;
6. number of pulmonary exacerbations, as measured using the
measure specified in the methodology of each trial, e.g.
modified Fuchs criteria (Bilton 2011).
We will generate a table for each comparison that is presented in
the review (e.g. intervention versus standard care; and intervention
versus active control group).
We will use the five GRADE considerations (risk of bias, consistency
of eBect, imprecision, indirectness and publication bias) to assess
the certainty of the body of evidence for each outcome, and to
draw conclusions about the certainty of evidence in the review
(Schünemann 2019).
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Appendix 1. Search Methods – Electronic Searches
 
Database/Resource Strategy
PubMed #1 randomized controlled trial [pt]
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(1946 to present) #2 controlled clinical trial [pt]
#3 randomized [tiab]
#4 placebo [tiab]




#9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
#10 animals [mh] NOT humans [mh]
#11 #9 NOT #10
#12 cystic fibrosis"[MeSH Terms] OR "cystic fibrosis" OR mucoviscidosis OR mucoviscidose
#13 adhere OR adherence OR adhered OR nonadherence OR persist OR persistance OR persisted
OR compliance OR comply OR complied OR noncompliance OR concordance OR non concordance
OR cooperative OR cooperation OR cooperate OR cooperated OR uncooperative OR conform
#14 "psychology"[MeSH Terms] OR "mind-body therapies"[MeSH Terms] OR "psychothera-
py"[MeSH Terms] OR "psychology, applied"[MeSH Terms] OR "neuropsychology"[MeSH Terms] OR
Psycholog* OR Psychosocial OR psychotherapy OR psychotherapies OR psychotherapist OR psy-
choanal* OR psychodrama OR behavio* OR attitude* OR communicat* OR reward* OR remind* OR
educate OR education OR supervis* OR family* OR families OR train* OR monitor* OR problem* OR
team* OR diary OR diaries OR counsel* OR feedback OR reinforc* OR motivat* OR self-regulat* OR
cope OR coping OR emotion* OR social* OR sociol* OR cognitive OR cognition OR mental* OR ver-
bal* OR construct OR crisis OR aversion OR assertiv* OR accept* OR mind OR mindful* OR mood*
OR support* OR wellness OR habit* OR talk* OR depress* OR goal* OR support* OR hypnosis OR
hypnotherap*
#15 #11 AND #12 AND #13 AND #14
*NOTE: Lines #1- #11 are the Cochrane Highly Sensitive Search Strategy for identifying randomized tri-
als in MEDLINE: sensitivity-maximizing version (2008 revision); PubMed format
PsychINFO Ovid
(1806 to present)
Search terms to be based on PubMed search strategy
Scopus
(1823 to present)
1 cystic fibrosis OR mucoviscidosis OR mucoviscidose [Article title, Abstract, Keywords]
2 adhere OR adherence OR adhered OR nonadherence OR persist OR persistance OR persisted OR
compliance OR comply OR complied OR noncompliance OR concordance OR non concordance OR
cooperative OR cooperation OR cooperate OR cooperated OR uncooperative OR conform
3 Psycho* OR behavio* OR attitude* OR communicat* OR reward* OR remind* OR educat* OR su-
pervis* OR famil* OR train* OR monitor* OR problem* OR team* OR diar* OR counsel* OR feedback
OR reinforc* OR motivat* OR self-regulat* OR cope OR coping OR emotion*
4 social* OR socio* OR cognitive OR mental* OR verbal* OR condition* OR knowledge OR personal
OR construct OR crisis OR aversion OR assertiv* OR Accept* OR commit* OR mind* OR mood* OR
support* OR well* OR habit* OR talk* OR depress*
5 #3 OR #4
6 #1 AND #2 AND #5
  (Continued)
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*NOTE: maximum number of characters exceeded in Line #3, so psychological search terms divided in-
to two search lines and combined using OR operator (Line #5)
OpenGrey (cystic fibrosis OR mucoviscidosis OR mucoviscidose) AND (adhere OR adherence OR adhered OR
nonadherence OR persist OR persistance OR persisted OR compliance OR comply OR complied OR
noncompliance OR concordance OR non concordance OR cooperative OR cooperation OR cooper-
ate OR cooperated OR uncooperative OR conform)
Clinicaltrials.gov [Advanced Search]
CONDITION/ DISEASE: cystic fibrosis OR mucoviscidosis OR mucoviscidose
OTHER TERMS: adhere OR adherence OR adhered OR nonadherence OR persist OR persistance OR
persisted OR compliance OR comply OR complied OR noncompliance OR concordance OR non con-
cordance OR cooperative OR cooperation OR cooperate OR cooperated OR uncooperative OR con-
form
STUDY TYPE: Interventional Studies (Clinical Trials)
WHO ICTRP Search terms to be based on Clinicaltrials.gov search strategy
  (Continued)
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C O N T R I B U T I O N S   O F   A U T H O R S
 
Task Author(s) responsible
Protocol stage: draP the protocol SD; LC
Review stage: select which trials to include (2 + 1 arbiter) SD; LC; CG; DCC
Review stage: extract data from trials (2 people) SD; LC
Review stage: enter data into RevMan SD
Review stage: carry out the analysis SD; LC; DCC
Review stage: interpret the analysis SD; LC; DCC
Review stage: draP the final review SD; LC; CG; DCC
Update stage: update the review SD
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SD is employed by Nottingham University Hospitals NHS Trust to work on the CFHealthHub Data Observatory, which aims to embed
objective adherence data into routine CF care using quality improvement cycles. She has not had any involvement in the CFHealthHub RCT
which took place at 19 CF Centres across the UK to evaluate a complex behaviour change intervention to support adherence to inhaled
therapies in people with CF.
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